BIM deletion polymorphism profiling complements prognostic values of risk scores in imatinib-treated Asian chronic myeloid leukemia patients

Leuk Lymphoma. 2019 Jan;60(1):234-237. doi: 10.1080/10428194.2018.1461863. Epub 2018 Jun 19.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use*
  • Asian People / genetics
  • Bcl-2-Like Protein 11 / genetics*
  • Biomarkers, Tumor / genetics*
  • Female
  • Humans
  • Imatinib Mesylate / therapeutic use*
  • Kaplan-Meier Estimate
  • Leukemia, Myeloid, Chronic-Phase / drug therapy*
  • Leukemia, Myeloid, Chronic-Phase / genetics
  • Leukemia, Myeloid, Chronic-Phase / mortality
  • Male
  • Middle Aged
  • Polymorphism, Genetic
  • Predictive Value of Tests
  • Prognosis
  • Sequence Deletion
  • Treatment Outcome
  • Young Adult

Substances

  • Antineoplastic Agents
  • BCL2L11 protein, human
  • Bcl-2-Like Protein 11
  • Biomarkers, Tumor
  • Imatinib Mesylate